Alnylam Pharmaceuticals.
biopharmaceutical company
- Reports this week
- 3
- Active events
- 0
- Connections
- 96
What's happening
Earlier this month
-
AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Some support3 reports
-
Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.Some support2 reports
-
Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.Some support8 reports
One to three months ago
-
Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.Some support1 report
-
Someone sold shares of Netflix, Alnylam Pharmaceuticals, JD.com, and Amazon.com on August 11th.Some support1 report
-
Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.Some support1 report
-
Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.Well supported7 reports
-
Dr. Sah, who was previously employed by Alnylam Pharmaceuticals, was mentioned in a recent report.Some support1 report
-
Alnylam Pharmaceuticals is trading on the Nasdaq stock exchange and is receiving analyst coverage and target price reports.Some support2 reports
Gone quiet
No new reports in 90+ days-
Bank of America, Truist Financial, and Royal Bank of Canada lowered price targets for Alnylam Pharmaceuticals on July 14, 2026.Some support7 reports
-
Multiple companies, including AbbVie, Amgen, and Alnylam, saw analyst target prices adjusted on July 13, 2026, including raises and cuts.Some support1 report
-
Alnylam Pharmaceuticals and Eli Lilly are competing in the biopharmaceutical market, with high trading volume driving market coverage by MarketBeat.Some support1 report
-
Pyott family provided a £25 million gift to London Business School, where David E.I. Pyott serves as a director and trustee.Some support1 report
-
Analyst upgrades were issued for several companies on June 29, including Alnylam Pharmaceuticals, Plug Power, Palantir Technologies, Citi Trends, and others.Some support1 report
-
Analyst downgrades affect the stock ratings of Alnylam Pharmaceuticals and Camden Property Trust.Some support1 report
-
Institutional investors, including Capital Research Global Investors and Geode Capital Management, increased their stake in Alnylam Pharmaceuticals, requiring SEC filings.Some support1 report
-
Alnylam Pharmaceuticals and Inceptive Nucleics are involved in strategic developments, including trading on the exchange and pursuing collaborations to accelerate therapeutics innovation.Some support1 report
-
The European Commission approved Alnylam's AMVUTTRA, and Dr. Pushkal Garg was appointed to accelerate R&D efforts.Speculative1 report
-
RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.Speculative2 reports
-
BMO Capital maintained an 'Outperform' rating on Alnylam Pharmaceuticals on June 30, 2025.Speculative1 report
-
Li Lu provided commentary on investment risk factors concerning Alnylam Pharmaceuticals on July 17, 2025.Some support1 report
-
William Blair issued a positive outlook on Alnylam Pharmaceuticals on August 2, 2025.Some support1 report
-
Alnylam is headquartered in Cambridge, MA, and engages with users on X (formerly Twitter), LinkedIn, and Instagram. Novartis and Sanofi are partners in commercializing Alnylam products.Some support2 reports
-
Alnylam Pharmaceuticals received regulatory approval for its lead drug in both the US and Europe.Some support2 reports
-
Yvonne Greenstreet, CEO & Director of Alnylam Pharmaceuticals, sold company shares.Some support2 reports
-
Alnylam Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress in Madrid, Spain.Some support2 reports
-
FDA approved multiple Alnylam therapeutics for the company based in Cambridge, MA.Some support1 report1 development inside
-
Warren Buffett provided commentary on investment risk, using Alnylam Pharmaceuticals as a subject of stock analysis.Some support1 report
-
Synopsys and Alnylam Pharmaceuticals were operating and trading within the U.S. stock market on August 19, 2025.Some support1 report
-
Alnylam Pharmaceuticals signed a license and research agreement with Scenic Biotech for RNAi therapeutics.Some support1 report
-
A report was issued from Dublin involving Alnylam Pharmaceuticals on August 28, 2025.Some support1 report
-
Novartis acquired Medicines Co., which was partnered with Alnylam. John Maraganore was a founder of Alnylam Pharmaceuticals.Some support2 reports
-
Alnylam Pharmaceuticals filed disclosures regarding its share holdings with the SEC on May 27, 2026.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Alnylam Pharmaceuticals
Events traced to Alnylam Pharmaceuticals, step by step, newest firstAround Alnylam Pharmaceuticals this week
News at the entities that move Alnylam Pharmaceuticals most-
FDA StructuralTraceLink advances multinational compliance roadmaps in Egypt and Ethiopia while addressing FDA's transition to 12-digit National Drug Code.Moves Alnylam Pharmaceuticals
-
Nasdaq StructuralMedallion, a company, issued a news release from New York City.Moves Alnylam Pharmaceuticals
-
AstraZeneca OperationalA joint venture involving AstraZeneca and Ericsson, supported by Sweden, was formed to launch a Sferical AI supercomputer.Moves Alnylam Pharmaceuticals
-
Securities and Exchange Commission StructuralCitigroup reaffirmed an outperform rating on Barrett Business Services, Inc. while the SEC mandated 13F filings for investment disclosures.Moves Alnylam Pharmaceuticals
-
Capital Research Global Investors TransactionalInvestment firms have acquired new and boosted stakes in TSMC shares.Moves Alnylam Pharmaceuticals
-
board of directors StructuralThe Board of Directors of Glunz & Jensen Holding A/S reviewed and approved the company's financial report on October 19, 2026.Moves Alnylam Pharmaceuticals
Connections
The 36 strongest of 96, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
John Maraganore Structural
John Maraganore served as a founder and CEO of Alnylam Pharmaceuticals from 2002 to 2021.
-
Nasdaq Structural
Alnylam Pharmaceuticals is a publicly traded company listed on the Nasdaq exchange.
-
AstraZeneca Operational
The companies are direct competitors in the ATTR-CM indication while also maintaining a formal partnership on drug development.
-
Securities and Exchange Commission Structural
A company is subject to mandatory filings with the SEC regarding its share holdings and market activities.
-
FDA Structural
The FDA regulates Alnylam Pharmaceuticals, with regulatory approvals directly impacting the company's pipeline and revenue.
-
Hoffmann-La Roche Operational
Alnylam and Roche maintain an ongoing operational partnership involving joint drug development and milestone payments.
-
Yvonne Greenstreet Structural
Yvonne Greenstreet serves as the Chief Executive Officer and Director of Alnylam Pharmaceuticals.
-
Capital Research Global Investors Transactional
Capital Research Global Investors made specific investment decisions, including increasing and decreasing its stake in Alnylam Pharmaceuticals.
Show all 36 connections
-
board of directors Structural
The company relies on its board of directors for governance and oversight.
-
SEC Structural
Alnylam Pharmaceuticals is subject to formal regulatory oversight by the SEC regarding financial and insider trading disclosures.
-
BridgeBio Operational
BridgeBio and Alnylam Pharmaceuticals are active competitors vying for market share in the ATTR-CM therapeutic area.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides analyst coverage and target price reports for Alnylam Pharmaceuticals.
-
Pfizer Operational
Alnylam and Pfizer are direct competitors in the ATTR-CM therapeutic market.
-
Novartis Structural
Novartis and Alnylam maintain a structural partnership where Novartis is responsible for commercializing Alnylam's therapeutic products.
-
Eli Lilly and Company Operational
The two companies actively compete for market share within the advanced biopharmaceutical sector.
-
Geode Capital Management Transactional
Geode Capital Management increased its investment holdings in Alnylam Pharmaceuticals.
-
Brown Advisory Transactional
Brown Advisory invested its proceeds into Alnylam Pharmaceuticals.
-
Ionis Pharmaceuticals Operational
Alnylam and Ionis are currently partnered for clinical trials while also operating in a competitive market environment.
-
David E.I. Pyott Structural
David E.I. Pyott serves as a director on the board of Alnylam Pharmaceuticals.
-
MarketBeat Mentioned together
MarketBeat provides market coverage, tracking, and average ratings for Alnylam Pharmaceuticals.
-
Bank of America Mentioned together
Bank of America provides financial coverage, including buy ratings and price objectives, for Alnylam Pharmaceuticals.
-
Truist Financial Transactional
Truist Financial issued analyst ratings and reduced price targets for Alnylam Pharmaceuticals.
-
Raymond James Financial Operational
Raymond James Financial upgraded Alnylam Pharmaceuticals' rating, indicating market interaction.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis and price targets for Alnylam Pharmaceuticals.
-
Benzinga Mentioned together
Benzinga reports on Alnylam's stock news.
-
TD Cowen Mentioned together
TD Cowen provided analyst coverage on Alnylam, reaffirming a buy rating.
-
Instagram Operational
Alnylam Pharmaceuticals actively uses Instagram as a platform to engage with its users.
-
LinkedIn Shared context
Alnylam Pharmaceuticals uses LinkedIn as a platform to engage with users.
-
AstraZeneca Operational
The relationship is characterized by competitive influence where clinical failures of rival drugs affect the risk profiles of both companies.
-
Europe Shared context
Alnylam Pharmaceuticals operates within the regulatory framework of Europe, receiving drug approvals from European bodies.
-
Emergent BioSolutions Operational
Both companies are actively competing for investment within the healthcare sector.
-
Norges Bank Transactional
Norges Bank has acquired a new investment position in Alnylam Pharmaceuticals through share purchases.
-
Citigroup Mentioned together
Citigroup provides market coverage and analysis on Alnylam Pharmaceuticals.
-
Needham & Company Operational
Needham & Company provided investment ratings and target price adjustments for Alnylam Pharmaceuticals.
-
AbbVie Mentioned together
Financial analysis suggests a target price increase related to the entities.
-
Cambridge Shared context
Alnylam Pharmaceuticals is headquartered in Cambridge, MA.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
2 eventsJuly 2026
5 events- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Bank of America, Truist Financial, and Royal Bank of Canada lowered price targets for Alnylam Pharmaceuticals on July 14, 2026.
- Multiple companies, including AbbVie, Amgen, and Alnylam, saw analyst target prices adjusted on July 13, 2026, including raises and cuts.
- Alnylam Pharmaceuticals and Eli Lilly are competing in the biopharmaceutical market, with high trading volume driving market coverage by MarketBeat.
- Pyott family provided a £25 million gift to London Business School, where David E.I. Pyott serves as a director and trustee.
Show 1 earlier month
June 2026
24 events- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
- Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.
- Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
- Alnylam Pharmaceuticals is trading on the Nasdaq stock exchange and is receiving analyst coverage and target price reports.
- Analyst upgrades were issued for several companies on June 29, including Alnylam Pharmaceuticals, Plug Power, Palantir Technologies, Citi Trends, and others.
- Analyst downgrades affect the stock ratings of Alnylam Pharmaceuticals and Camden Property Trust.
- Institutional investors, including Capital Research Global Investors and Geode Capital Management, increased their stake in Alnylam Pharmaceuticals, requiring SEC filings.
- Alnylam Pharmaceuticals and Inceptive Nucleics are involved in strategic developments, including trading on the exchange and pursuing collaborations to accelerate therapeutics innovation.
- The European Commission approved Alnylam's AMVUTTRA, and Dr. Pushkal Garg was appointed to accelerate R&D efforts.
- RBC raised price target on Alnylam Pharmaceuticals on July 7, 2025.
- BMO Capital maintained an 'Outperform' rating on Alnylam Pharmaceuticals on June 30, 2025.
- Li Lu provided commentary on investment risk factors concerning Alnylam Pharmaceuticals on July 17, 2025.
- William Blair issued a positive outlook on Alnylam Pharmaceuticals on August 2, 2025.
- Alnylam is headquartered in Cambridge, MA, and engages with users on X (formerly Twitter), LinkedIn, and Instagram. Novartis and Sanofi are partners in commercializing Alnylam products.
- Alnylam Pharmaceuticals received regulatory approval for its lead drug in both the US and Europe.
- Yvonne Greenstreet, CEO & Director of Alnylam Pharmaceuticals, sold company shares.
- Alnylam Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress in Madrid, Spain.
- FDA approved multiple Alnylam therapeutics for the company based in Cambridge, MA.
- Warren Buffett provided commentary on investment risk, using Alnylam Pharmaceuticals as a subject of stock analysis.
- Synopsys and Alnylam Pharmaceuticals were operating and trading within the U.S. stock market on August 19, 2025.
- Alnylam Pharmaceuticals signed a license and research agreement with Scenic Biotech for RNAi therapeutics.
- A report was issued from Dublin involving Alnylam Pharmaceuticals on August 28, 2025.
- Novartis acquired Medicines Co., which was partnered with Alnylam. John Maraganore was a founder of Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals filed disclosures regarding its share holdings with the SEC on May 27, 2026.